MUW and MSD Poland continue cooperation for public health

The agreement continuing the strategic partnership between the institutions was signed by Prof. Piotr Pruszczyk, Vice Rector for Science and Technology Transfer, on the part of MUW, and Justin Gandy, Managing Director, on the part of MSD Poland. The goal of the cooperation is to improve the quality of healthcare in the long term based on data from actual clinical practice.

- I am glad that we are deepening our cooperation with MSD Poland - stressed Prof. Piotr Pruszczyk - The development of our strategic partnership has a chance to contribute to the improvement of patients' health situation.
- We are proud and excited to begin the next phase of cooperation with the Medical University of Warsaw - said Justin Gandy, emphasizing that joint research activities have the potential to contribute to meeting the health needs of Polish patients and improving the quality of health care.

The meeting, during which the agreement was signed, was also attended by Anna Staniszewska, MD, PhD, from the Department of Experimental and Clinical Pharmacology MUW, Maciej Niewada, MD, PhD, representing the Department of Experimental and Clinical Pharmacology MUW, Anna Kula, director of the Technology Transfer Office MUW, and from the MSD side: Marcin Bodio, Dawid Grzeszczuk, Daniel Szulczyk.

The beginnings of cooperation

The cooperation between MUW and MSD Poland began in February 2023 with the signing of a bilateral declaration of cooperation. Its goal was to initiate a long-term partnership in health care, focusing on improving healthcare standards and therapeutic outcomes.

In November 2023, the parties entered into the first executive agreement under MSD's "CORE Partnership Program (Center for Observational and Real-World Evidence)". Under it, a multidisciplinary team of scientists and physicians undertook an analysis of the effects of recurrence in selected cancers from the perspective of a public health care provider.

- The results of the analysis can help understand priorities in oncology care investments and clarify the economic and systemic consequences of the decisions taken so far - explains Anna Staniszewska, MD, PhD. And she emphasizes that the use of real-world evidence in health care contributes to improving the quality of patient treatment through real-world information on which health interventions work best.